 |
2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Spinocerebellar ataxia |
| USA Market Approval | USA |
| USA Designation Date | 2016-05-18 00:00:00 |
| Sponsor | Biohaven Pharmaceuticals, Inc.;234 Church Street, Suite 304;New Haven, Connecticut, 06510 |
